Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
$0.41
-4.7%
$0.43
$0.32
$0.75
$20.63M-0.1213,133 shs341,644 shs
MTO
Metanor Resources Inc. (MTO.V)
C$0.58
C$0.58
C$0.46
C$0.82
C$59.13MN/A80,421 shs232,400 shs
Paymentus Holdings, Inc. stock logo
PAY
Paymentus
$20.12
-2.4%
$19.88
$7.76
$25.21
$2.49B1.52292,785 shs148,304 shs
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
-5.47%-13.16%-7.61%+0.87%-17.81%
MTO
Metanor Resources Inc. (MTO.V)
0.00%0.00%0.00%0.00%0.00%
Paymentus Holdings, Inc. stock logo
PAY
Paymentus
-2.42%+2.60%-12.90%+24.35%+148.40%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
N/AN/AN/AN/AN/AN/AN/AN/A
MTO
Metanor Resources Inc. (MTO.V)
N/AN/AN/AN/AN/AN/AN/AN/A
Paymentus Holdings, Inc. stock logo
PAY
Paymentus
0.8753 of 5 stars
1.13.00.00.01.90.82.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
N/AN/AN/AN/A
MTO
Metanor Resources Inc. (MTO.V)
N/AN/AN/AN/A
Paymentus Holdings, Inc. stock logo
PAY
Paymentus
2.13
Hold$17.81-11.47% Downside

Current Analyst Ratings

Latest EQN, PAY, AIM, MTO, and KGH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/15/2024
Paymentus Holdings, Inc. stock logo
PAY
Paymentus
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$20.00 ➝ $22.50
4/12/2024
Paymentus Holdings, Inc. stock logo
PAY
Paymentus
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$20.00 ➝ $22.00
3/14/2024
Paymentus Holdings, Inc. stock logo
PAY
Paymentus
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
3/6/2024
Paymentus Holdings, Inc. stock logo
PAY
Paymentus
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$17.00 ➝ $19.00
3/5/2024
Paymentus Holdings, Inc. stock logo
PAY
Paymentus
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$18.00 ➝ $20.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
$202K102.13N/AN/A$0.20 per share2.03
MTO
Metanor Resources Inc. (MTO.V)
C$26.37M2.24C$0.01 per share64.44C$0.20 per share2.97
Paymentus Holdings, Inc. stock logo
PAY
Paymentus
$614.49M4.06$0.52 per share38.86$3.47 per share5.80

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
-$28.96M-$0.60N/AN/A-14,337.62%-121.69%-97.91%5/13/2024 (Estimated)
MTO
Metanor Resources Inc. (MTO.V)
N/A-C$0.27N/AN/AN/AN/AN/AN/A
Paymentus Holdings, Inc. stock logo
PAY
Paymentus
$22.32M$0.18111.7844.71N/A3.63%7.42%6.34%5/6/2024 (Confirmed)

Latest EQN, PAY, AIM, MTO, and KGH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2024N/A
Paymentus Holdings, Inc. stock logo
PAY
Paymentus
$0.08N/A-$0.08N/AN/AN/A  
3/4/202412/31/2023
Paymentus Holdings, Inc. stock logo
PAY
Paymentus
$0.06$0.09+$0.03$0.11$157.38 million$164.80 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
N/AN/AN/AN/AN/A
MTO
Metanor Resources Inc. (MTO.V)
N/AN/AN/AN/AN/A
Paymentus Holdings, Inc. stock logo
PAY
Paymentus
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
N/A
1.68
1.68
MTO
Metanor Resources Inc. (MTO.V)
12.70
0.58
0.27
Paymentus Holdings, Inc. stock logo
PAY
Paymentus
N/A
4.31
4.31

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
12.02%
MTO
Metanor Resources Inc. (MTO.V)
N/A
Paymentus Holdings, Inc. stock logo
PAY
Paymentus
12.55%

Insider Ownership

CompanyInsider Ownership
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
0.02%
MTO
Metanor Resources Inc. (MTO.V)
N/A
Paymentus Holdings, Inc. stock logo
PAY
Paymentus
17.60%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
2650.75 million50.74 millionNot Optionable
MTO
Metanor Resources Inc. (MTO.V)
N/A101.95 millionN/ANot Optionable
Paymentus Holdings, Inc. stock logo
PAY
Paymentus
1,273123.92 million102.11 millionOptionable

EQN, PAY, AIM, MTO, and KGH Headlines

SourceHeadline
Paymentus (NYSE:PAY) Share Price Crosses Above 200-Day Moving Average of $17.62Paymentus (NYSE:PAY) Share Price Crosses Above 200-Day Moving Average of $17.62
americanbankingnews.com - April 23 at 3:02 AM
Paymentus (NYSE:PAY) Share Price Crosses Above Two Hundred Day Moving Average of $17.62Paymentus (NYSE:PAY) Share Price Crosses Above Two Hundred Day Moving Average of $17.62
marketbeat.com - April 23 at 2:58 AM
Paymentus to Report First Quarter 2024 Earnings Results and Host Webcast on May 6, 2024Paymentus to Report First Quarter 2024 Earnings Results and Host Webcast on May 6, 2024
businesswire.com - April 22 at 4:05 PM
Paymentus (NYSE:PAY) Price Target Raised to $22.50 at The Goldman Sachs GroupPaymentus (NYSE:PAY) Price Target Raised to $22.50 at The Goldman Sachs Group
americanbankingnews.com - April 16 at 4:26 AM
Paymentus (NYSE:PAY) Given New $22.50 Price Target at The Goldman Sachs GroupPaymentus (NYSE:PAY) Given New $22.50 Price Target at The Goldman Sachs Group
marketbeat.com - April 15 at 11:21 AM
Hold Rating on Paymentus Amid Rising Energy Prices and Inflationary PressuresHold Rating on Paymentus Amid Rising Energy Prices and Inflationary Pressures
markets.businessinsider.com - April 12 at 8:19 AM
Expert Outlook: Paymentus Holdings Through The Eyes Of 4 AnalystsExpert Outlook: Paymentus Holdings Through The Eyes Of 4 Analysts
markets.businessinsider.com - April 12 at 8:19 AM
Robert W. Baird Increases Paymentus (NYSE:PAY) Price Target to $22.00Robert W. Baird Increases Paymentus (NYSE:PAY) Price Target to $22.00
marketbeat.com - April 12 at 8:14 AM
Paymentus: Robust Business With Secular CatalystPaymentus: Robust Business With Secular Catalyst
seekingalpha.com - April 11 at 10:29 AM
Is Paymentus (PAY) Stock Outpacing Its Business Services Peers This Year?Is Paymentus (PAY) Stock Outpacing Its Business Services Peers This Year?
zacks.com - April 10 at 10:46 AM
Wakefield Asset Management LLLP Invests $875,000 in Paymentus Holdings, Inc. (NYSE:PAY)Wakefield Asset Management LLLP Invests $875,000 in Paymentus Holdings, Inc. (NYSE:PAY)
marketbeat.com - April 8 at 8:37 AM
Paymentus Holdings, Inc. (NYSE:PAY) Receives Consensus Recommendation of "Hold" from AnalystsPaymentus Holdings, Inc. (NYSE:PAY) Receives Consensus Recommendation of "Hold" from Analysts
marketbeat.com - April 1 at 6:14 AM
3 Stocks That Are Completely Underestimated by Wall Street3 Stocks That Are Completely Underestimated by Wall Street
investorplace.com - March 31 at 3:57 PM
Paymentus (NYSE:PAY) Stock Price Down 3%Paymentus (NYSE:PAY) Stock Price Down 3%
marketbeat.com - March 26 at 4:22 PM
Paymentus Holdings, Inc. (PAY) Hits Fresh High: Is There Still Room to Run?Paymentus Holdings, Inc. (PAY) Hits Fresh High: Is There Still Room to Run?
zacks.com - March 26 at 10:16 AM
Heres Why Paymentus (PAY) is a Strong Momentum StockHere's Why Paymentus (PAY) is a Strong Momentum Stock
zacks.com - March 25 at 10:56 AM
Are Business Services Stocks Lagging Paymentus (PAY) This Year?Are Business Services Stocks Lagging Paymentus (PAY) This Year?
zacks.com - March 25 at 10:41 AM
Strength Seen in Paymentus (PAY): Can Its 7.8% Jump Turn into More Strength?Strength Seen in Paymentus (PAY): Can Its 7.8% Jump Turn into More Strength?
zacks.com - March 21 at 9:15 AM
PAY Apr 2024 20.000 callPAY Apr 2024 20.000 call
ca.finance.yahoo.com - March 15 at 11:45 PM
PAY Apr 2024 7.500 putPAY Apr 2024 7.500 put
ca.finance.yahoo.com - March 15 at 11:45 PM
Buy 5 High-Flying Technology Services Stocks With Room to GrowBuy 5 High-Flying Technology Services Stocks With Room to Grow
zacks.com - March 14 at 10:41 AM
Are You Looking for a Top Momentum Pick? Why Paymentus (PAY) is a Great ChoiceAre You Looking for a Top Momentum Pick? Why Paymentus (PAY) is a Great Choice
zacks.com - March 13 at 1:00 PM
Paymentus Holdings Incs SVP and CFO Sanjay Kalra Sells 65,855 SharesPaymentus Holdings Inc's SVP and CFO Sanjay Kalra Sells 65,855 Shares
finance.yahoo.com - March 12 at 12:43 AM
Paymentus Holdings Full Year 2023 Earnings: Beats ExpectationsPaymentus Holdings Full Year 2023 Earnings: Beats Expectations
finance.yahoo.com - March 10 at 1:46 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

AIM ImmunoTech logo

AIM ImmunoTech

NYSE:AIM
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; Pharmaceutics International Inc.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Metanor Resources Inc. (MTO.V)

CVE:MTO
Metanor Resources Inc. produces and sells gold in Canada. It also explores for and develops mining properties. The company primarily holds interests in the Bachelor mine and the Barry project, as well as approximately 15,000 hectares of exploration properties located in the mining-friendly jurisdiction of Québec. Metanor Resources Inc. was incorporated in 2003 and is headquartered in Val-d'Or, Canada.
Paymentus logo

Paymentus

NYSE:PAY
Paymentus Holdings, Inc. provides cloud-based bill payment technology and solutions in the United States and internationally. The company offers electronic bill presentment and payment services, enterprise customer communication, and self-service revenue management to billers through a software-as-a-service technology platform. Its platform's payment processing includes credit cards, debit cards, eChecks, and digital wallets. It serves utility, financial service, government, insurance, telecommunication, real estate management, education, consumer finance, healthcare, and small business industries. The company was founded in 2004 and is headquartered in Charlotte, North Carolina.